Literature DB >> 23328556

Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.

Gerald S Falchook1, Filip Janku, Anne S Tsao, Christel C Bastida, David J Stewart, Razelle Kurzrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23328556      PMCID： PMC3551245          DOI： 10.1097/JTO.0b013e31827ce38e

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Lynne Bemis; Marileila Varella-Garcia
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

2.  Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.

Authors:  Andrew J Weickhardt; Tim J Price; Geoff Chong; Val Gebski; Nick Pavlakis; Terrance G Johns; Arun Azad; Effie Skrinos; Kate Fluck; Alexander Dobrovic; Renato Salemi; Andrew M Scott; John M Mariadason; Niall C Tebbutt
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

3.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Authors:  Shizhen Emily Wang; Archana Narasanna; Marianela Perez-Torres; Bin Xiang; Frederick Y Wu; Seungchan Yang; Graham Carpenter; Adi F Gazdar; Senthil K Muthuswamy; Carlos L Arteaga
Journal:  Cancer Cell       Date:  2006-07       Impact factor: 31.743

4.  Survival of cancer cells is maintained by EGFR independent of its kinase activity.

Authors:  Zhang Weihua; Rachel Tsan; Wei-Chien Huang; Qiuyu Wu; Chao-Hua Chiu; Isaiah J Fidler; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

5.  Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Authors:  Philip Stephens; Chris Hunter; Graham Bignell; Sarah Edkins; Helen Davies; Jon Teague; Claire Stevens; Sarah O'Meara; Raffaella Smith; Adrian Parker; Andy Barthorpe; Matthew Blow; Lisa Brackenbury; Adam Butler; Oliver Clarke; Jennifer Cole; Ed Dicks; Angus Dike; Anja Drozd; Ken Edwards; Simon Forbes; Rebecca Foster; Kristian Gray; Chris Greenman; Kelly Halliday; Katy Hills; Vivienne Kosmidou; Richard Lugg; Andy Menzies; Janet Perry; Robert Petty; Keiran Raine; Lewis Ratford; Rebecca Shepherd; Alexandra Small; Yvonne Stephens; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Margaret Knowles; Suet Y Leung; David N Louis; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin Teh; Georgia Chenevix-Trench; Barbara L Weber; Siu T Yuen; Grace Harris; Peter Goldstraw; Andrew G Nicholson; P Andrew Futreal; Richard Wooster; Michael R Stratton
Journal:  Nature       Date:  2004-09-30       Impact factor: 49.962
  5 in total
  18 in total

Review 1.  Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Authors:  Janakiraman Subramanian; Archana Katta; Ashiq Masood; Dashavantha Reddy Vudem; Rama Krishna Kancha
Journal:  Oncologist       Date:  2019-07-10

2.  HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Authors:  Rathi N Pillai; Madhusmita Behera; Lynne D Berry; Mike R Rossi; Mark G Kris; Bruce E Johnson; Paul A Bunn; Suresh S Ramalingam; Fadlo R Khuri
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860

3.  A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Authors:  Gerald S Falchook; Stacy Moulder; Aung Naing; Jennifer J Wheler; David S Hong; Sarina A Piha-Paul; Apostolia M Tsimberidou; Siqing Fu; Ralph Zinner; Filip Janku; Yunfang Jiang; Mei Huang; Kristin L Parkhurst; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2014-10-18       Impact factor: 3.850

4.  Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations.

Authors:  Mina Nikanjam; Shumei Kato; Jacob J Adashek; Razelle Kurzrock
Journal:  Clin Oncol Case Rep       Date:  2021-12-15

Review 5.  New therapeutic approaches to overcoming resistant EGFR exon 20 alterations.

Authors:  Alex M Li; Amélie Boichard; Enriqueta Felip; Razelle Kurzrock
Journal:  Crit Rev Oncol Hematol       Date:  2020-05-20       Impact factor: 6.312

Review 6.  Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.

Authors:  Alona Zer; Natasha Leighl
Journal:  Front Oncol       Date:  2014-11-25       Impact factor: 6.244

7.  HER2 expression status in diverse cancers: review of results from 37,992 patients.

Authors:  Min Yan; Maria Schwaederle; David Arguello; Sherri Z Millis; Zoran Gatalica; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

8.  A framework for genomic biomarker actionability and its use in clinical decision making.

Authors:  Smruti J Vidwans; Michelle L Turski; Filip Janku; Ignacio Garrido-Laguna; Javier Munoz; Richard Schwab; Vivek Subbiah; Jordi Rodon; Razelle Kurzrock
Journal:  Oncoscience       Date:  2014-10-22

9.  Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors.

Authors:  Alexej Ballhausen; Jennifer J Wheler; Daniel D Karp; Sarina A Piha-Paul; Siqing Fu; Shubham Pant; Apostolia M Tsimberidou; David S Hong; Vivek Subbiah; Veronica R Holley; Helen J Huang; Abenaa M Brewster; Kimberly B Koenig; Nuhad K Ibrahim; Funda Meric-Bernstam; Filip Janku
Journal:  Clin Cancer Res       Date:  2020-10-28       Impact factor: 12.531

10.  Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.

Authors:  Vijayalakshmi Ramshankar; Subha Yegnaswamy; Kumarasamy P; Krishnamurthy Arvind
Journal:  Bioinformation       Date:  2014-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.